RimabotulinumtoxinB (Myobloc)

Myobloc (rimabotulinumtoxinB) is covered only for FDA‑approved adult indications—cervical dystonia and chronic sialorrhea—and is not covered for other uses. Coverage requires age ≥18, documented diagnosis and planned dosing, for cervical dystonia documented failure or tolerance to onabotulinumtoxinA, dosing limits of ≤5,000 units (dystonia) or ≤3,500 units (sialorrhea) administered no more often than every 12 weeks, and approvals are limited to 12 months.

"Treatment of adults with cervical dystonia."

Sign up to see full coverage criteria, indications, and limitations.